Share |
News

T-Ray Science Announces Key Milestones Toward Commercialization


January 10, 2011 at 9:05 pm

UBC Research Agreement, Health Canada Ruling and Lease for  Manufacturing Space Secured for Innovative Cancer Detection Device

Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) (the “Company” or “T-Ray”) announced  a number of milestones today that will lead toward the commercialization of the Company’s cancer detection technology for skin cancer.

T-Ray has signed a research agreement with the Skin Care Centre at Vancouver General Hospital and the University of British Columbia (UBC), received a Health Canada ruling that will simplify the approval process for the Verisānte™ Aura™ device for skin cancer detection, and signed a lease for a manufacturing facility in Richmond, B.C.

“These announcements are indicative of the strong progress we are making towards commercializing the Verisānte™ Aura™ and bringing its benefits to market, including better patient outcomes, system-wide cost savings and immediate diagnoses, ” said Thomas Braun, CEO, T-Ray.

Today’s announcements include:

 

 

 

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company committed to  commercializing  innovative systems for the early detection of cancer. The Verisānte™ Core™ series for lung cancer detection and the Verisānte™ Aura™ for skin cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at VGH. This exclusive platform technology allows T-Ray to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers, including gastro-intestinal, colorectal and cervical cancers.

About the BC Cancer Agency

The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency. www.bccancer.bc.ca

About The Skin Care Centre at Vancouver General Hospital

The Skin Care Centre at VGH is affiliated with the UBC Department of Dermatology and Skin Sciences. It is a national centre of excellence uniting clinical care, research, and education. The Centre sees over 20,000 patients annually in general and subspecialty dermatology clinics, and runs the country's busiest phototherapy centre. A critical component of the Skin Care Centre at VGH is its comprehensive and aggressive program dedicated to exploring all aspects of skin cancer, encompassing treatment, clinical, and basic science research.  http://www.skincarecentre.ca/

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

T-Ray Science, Inc.
Thomas Braun, President & CEO   
Telephone: 1-877-605-0507

Email: info@t-rayscience.com
Website:  www.t-rayscience.com

Forward Looking Statements


This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

 

  Back to top